{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kim MS"],"funding":["Chonnam National University"],"pagination":["132-139"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8498686"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(3)"],"pubmed_abstract":["<h4>Purpose</h4>The aim of this study was to investigate the effect of androgen deprivation therapy (ADT) on the health-related quality of life (HRQOL) of patients with prostate cancer (PC) and compare the changes in the HRQOL between ADT alone and ADT plus intensity-modulated radiation therapy (IMRT).<h4>Materials and methods</h4>Patients with PC were prospectively recruited between October 2018 and April 2020. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and the PC-specific module (PR25) were administered before ADT (baseline) and at 3, 6, and 12 months after ADT. All patients received subcutaneous injections of 45 mg leuprolide acetate at 6-month intervals for 12 months.<h4>Results</h4>Fifty-five of the 71 patients (77.5%) completed the 12"],"journal":["Prostate international"],"pubmed_title":["Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study."],"pmcid":["PMC8498686"],"funding_grant_id":["HCRI 19017"],"pubmed_authors":["Kim MS","Jung SI","Chang Hwang E","Kwon D","Chung HS"],"additional_accession":[]},"is_claimable":false,"name":"Effects of leuprolide acetate on the quality of life of patients with prostate cancer: A prospective longitudinal cohort study.","description":"<h4>Purpose</h4>The aim of this study was to investigate the effect of androgen deprivation therapy (ADT) on the health-related quality of life (HRQOL) of patients with prostate cancer (PC) and compare the changes in the HRQOL between ADT alone and ADT plus intensity-modulated radiation therapy (IMRT).<h4>Materials and methods</h4>Patients with PC were prospectively recruited between October 2018 and April 2020. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and the PC-specific module (PR25) were administered before ADT (baseline) and at 3, 6, and 12 months after ADT. All patients received subcutaneous injections of 45 mg leuprolide acetate at 6-month intervals for 12 months.<h4>Results</h4>Fifty-five of the 71 patients (77.5%) completed the 12","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-19T15:09:11.741Z","creation":"2025-04-19T15:09:11.741Z"},"accession":"S-EPMC8498686","cross_references":{"pubmed":["34692585"],"doi":["10.1016/j.prnil.2020.11.001"]}}